IBDEI2FK ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41225,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,41225,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,41226,0)
 ;;=C94.41^^159^2004^16
 ;;^UTILITY(U,$J,358.3,41226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41226,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,41226,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,41226,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,41227,0)
 ;;=D62.^^159^2004^18
 ;;^UTILITY(U,$J,358.3,41227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41227,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,41227,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,41227,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,41228,0)
 ;;=C92.41^^159^2004^19
 ;;^UTILITY(U,$J,358.3,41228,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41228,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,41228,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,41228,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,41229,0)
 ;;=C92.40^^159^2004^20
 ;;^UTILITY(U,$J,358.3,41229,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41229,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,41229,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,41229,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,41230,0)
 ;;=D56.0^^159^2004^21
 ;;^UTILITY(U,$J,358.3,41230,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41230,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,41230,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,41230,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,41231,0)
 ;;=D63.1^^159^2004^23
 ;;^UTILITY(U,$J,358.3,41231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41231,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,41231,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,41231,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,41232,0)
 ;;=D63.0^^159^2004^24
 ;;^UTILITY(U,$J,358.3,41232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41232,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,41232,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,41232,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,41233,0)
 ;;=D63.8^^159^2004^22
 ;;^UTILITY(U,$J,358.3,41233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41233,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,41233,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,41233,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,41234,0)
 ;;=C22.3^^159^2004^26
 ;;^UTILITY(U,$J,358.3,41234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41234,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,41234,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,41234,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,41235,0)
 ;;=D61.9^^159^2004^27
 ;;^UTILITY(U,$J,358.3,41235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41235,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,41235,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,41235,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,41236,0)
 ;;=D56.1^^159^2004^29
 ;;^UTILITY(U,$J,358.3,41236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41236,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,41236,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,41236,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,41237,0)
 ;;=C83.79^^159^2004^31
 ;;^UTILITY(U,$J,358.3,41237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41237,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,41237,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,41237,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,41238,0)
 ;;=C83.70^^159^2004^32
 ;;^UTILITY(U,$J,358.3,41238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41238,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
